Activation of 5-HT1B/1D receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study

Yan, Qing‐Shan; Yan, Shu-E

doi:10.1016/s0014-2999(01)00913-x

Cited by 81 publications

(70 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that the administration of a 5-HT1B agonist, such as CP 93129, into the terminal region of this pathway, the NA, results in a local increase in DA (Hallbus et al, 1997;Yan and Yan, 2001a). It is doubtful that the relevant 5-HT1B receptors reside on dopaminergic terminals in the NA, as 5-HT1B receptor mRNA has not been detected in the cell body region for these projection neurons (Boschert et al, 1994;Bruinvels et al, 1994).…”

Section: Mesolimbic Pathwaymentioning

confidence: 99%

“…Administration of the 5-HT1B receptor agonist CP 93129 into the VTA has been shown to increase DA levels in the NA (Yan and Yan, 2001a;O'Dell and Parsons, 2004;Yan et al, 2004) and concurrently decrease GABA in the VTA (O'Dell and Parsons, 2004;Yan et al, 2004). Systemic 5-HT1B agonism also decreases VTA GABA (Parsons et al, 1999).…”

Section: Mesolimbic Pathwaymentioning

confidence: 99%

“…Coadministration of a 5-HT1B antagonist blocked the inhibitory effect of 5-HT on the GABA-B IPSP (Johnson et al, 1992;Cameron and Williams, 1995), while spiperone, an antagonist for 5-HT1A/2 receptors, did not (Johnson et al, 1992). Some investigators propose that the relevant 5-HT1B heteroreceptors are located on the axon terminals of GABAergic projection neurons from the NA (O'Dell and Yan and Yan 2001a). This proposed circuitry would parallel that of the nigrostriatal system where anatomical studies have provided strong evidence that 5-HT1B receptors are located on the terminals of striatonigral GABA neurons and modulate nigrostriatal DA release in a GABA-mediated manner (Bruinvels et al, 1994;Sari et al, 1999;Waeber and Palacios, 1989).…”

Section: Mesolimbic Pathwaymentioning

confidence: 99%

See 2 more Smart Citations

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

Alex

Pehek

2007

Pharmacology & Therapeutics

527

311

View full text Add to dashboard Cite

The neurotransmitter dopamine (DA) has a long association with normal functions such as motor control, cognition, and reward, as well as a number of syndromes including drug abuse, schizophrenia, and Parkinson's disease. Studies show that serotonin (5-HT) acts through several 5-HT receptors in the brain to modulate DA neurons in all three major dopaminergic pathways. There are at least 14 5-HT receptor subtypes, many of which have been shown to play some role in mediating 5-HT/DA interactions. Several subtypes, including the 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3 and 5-HT4 receptors, act to facilitate DA release, while the 5-HT2C receptor mediates an inhibitory effect of 5-HT on DA release. Most 5-HT receptor subtypes only modulate DA release when 5-HT and/or DA neurons are stimulated, but the 5-HT2C receptor, characterized by high levels of constitutive activity, inhibits tonic as well as evoked DA release. This review summarizes the anatomical evidence for the presence of each 5-HT receptor subtype in dopaminergic regions of the brain and the neuropharmacological evidence demonstrating regulation of each DA pathway. The relevance of 5-HT receptor modulation of DA systems to the development of therapeutics used to treat schizophrenia, depression, and drug abuse is discussed. Lastly, areas are highlighted in which future research would be maximally beneficial to the treatment of these disorders.

show abstract

Section: Mesolimbic Pathwaymentioning

confidence: 99%

Section: Mesolimbic Pathwaymentioning

confidence: 99%

Section: Mesolimbic Pathwaymentioning

confidence: 99%

See 1 more Smart Citation

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

Alex

Pehek

2007

Pharmacology & Therapeutics

527

311

View full text Add to dashboard Cite

show abstract

“…5-HT 1B receptors also function postsynaptically as inhibitory heteroreceptors to control the release of other neurotransmitters (Boschert et al, 1994;Moret and Briley, 1997;Adell et al, 2001). For example, 5-HT 1B receptors within the ventral tegmental area and nucleus accumbens modulate the release of dopamine in the terminal area of the mesolimbic system (Yan and Yan, 2001). As such, dysregulation of either 5-HT or other neurotransmitter targets could be responsible for the abnormal behavioral phenotype of female 5-HT 1B knockout mice.…”

Section: -Ht Depletionmentioning

confidence: 99%

Sex Differences in the Regulation of Serotonergic Transmission and Behavior in 5-HT Receptor Knockout Mice

Jones

Lucki

2005

Neuropsychopharmacol

100

View full text Add to dashboard Cite

Few studies have examined the relationship between genetics, stress, and sex-linked differences in neurotransmitter systems. Examining serotonin (5-HT) receptor knockout mice on stress-induced behavioral depression, female 5-HT 1B receptor knockout mice demonstrated significantly reduced immobility than either male 5-HT 1B receptor knockout mice or male and female wild-type mice on the tail suspension test (TST) and forced swimming test. The behavioral phenotype was identified as likely due to a disinhibition of 5-HT release, because depletion of 5-HT with parachlorophenylalanine selectively reduced immobility of female 5-HT 1B receptor knockout mice in the TST. In contrast, male and female 5-HT 1A receptor knockout mice demonstrated reduced immobility compared with control mice, but the depletion of 5-HT with PCPA did not reverse the antidepressant-like phenotype. Microdialysis studies confirmed significantly higher baseline levels of hippocampal 5-HT in female, but not male, 5-HT 1B receptor knockout mice. Both male and female 5-HT 1B receptor knockout mice demonstrated augmented dialysate responses to fluoxetine. Also, both male and female 5-HT 1B receptor knockout mice demonstrated reductions of immobility in the TST after treatment with fluoxetine. Therefore, female 5-HT 1B receptor knockout mice demonstrate a sex-linked disinhibition of 5-HT release that sustained higher baseline levels of hippocampal 5-HT and behavioral vulnerability to 5-HT depletion.

show abstract

“…In terms of this interaction, it is of interest to note that 5-HT 1B (Yan and Yan, 2001;Yan et al, 2004) and 5-HT 2A Table 1. The motor activity was automatically quantified and cumulated for 60 min following MAP challenge (0.24 mg/kg, s.c.) on days 29 and 13 of withdrawal of the repeated treatment with MAP (PT 1; pretreatment 1) and that with PRX (PT 2; pretreatment 2), respectively.…”

Section: Discussionmentioning

confidence: 99%

Selective Serotonin Reuptake Inhibitors, Fluoxetine and Paroxetine, Attenuate the Expression of the Established Behavioral Sensitization Induced by Methamphetamine

Kaneko

Kashiwa

Ito

et al. 2006

Neuropsychopharmacol

View full text Add to dashboard Cite

To obtain an insight into the development of a new pharmacotherapy that prevents the treatment-resistant relapse of psychostimulantinduced psychosis and schizophrenia, we have investigated in the mouse the effects of selective serotonin reuptake inhibitors (SSRI), fluoxetine (FLX) and paroxetine (PRX), on the established sensitization induced by methamphetamine (MAP), a model of the relapse of these psychoses, because the modifications of the brain serotonergic transmission have been reported to antagonize the sensitization phenomenon. In agreement with previous reports, repeated MAP treatment (1.0 mg/kg a day, subcutaneously (s.c.)) for 10 days induced a long-lasting enhancement of the increasing effects of a challenge dose of MAP (0.24 mg/kg, s.c.) on motor activity on day 12 or 29 of withdrawal. The daily injection of FLX (10 mg/kg, s.c.) or PRX (8 mg/kg, s.c.) from 12 to 16 days of withdrawal of repeated MAP administration markedly attenuated the ability of the MAP pretreatment to augment the motor responses to the challenge dose of the stimulant 13 days after the SSRI injection. The repeated treatment with FLX or PRX alone failed to affect the motor stimulation following the challenge of saline and MAP 13 days later. These results suggest that the intermittent and repetitive elevation of serotonergic tone may inhibit the expression of the motor sensitization induced by pretreatment with MAP. It is proposed that clinically available serotonin reuptake inhibitors could be useful for preventing the recurrence of hallucinatory-paranoid state in drug-induced psychosis and schizophrenia.

show abstract

Activation of 5-HT1B/1D receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study

Cited by 81 publications

References 43 publications

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

Sex Differences in the Regulation of Serotonergic Transmission and Behavior in 5-HT Receptor Knockout Mice

Selective Serotonin Reuptake Inhibitors, Fluoxetine and Paroxetine, Attenuate the Expression of the Established Behavioral Sensitization Induced by Methamphetamine

Contact Info

Product

Resources

About